Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183162 | 0.80 | LMNA (0.46) | L3MBTL1LMNATSHRSMN1; SMN2CA1 | |
| SCHEMBL3897867 | 0.79 | CA9 (0.39) | L3MBTL1LMNATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL6913359 | 0.78 | LMNA (0.44) | L3MBTL1LMNATSHRSMN1; SMN2CA1 | |
| SCHEMBL4760493 | 0.74 | — | — | |
| SCHEMBL8618817 | 0.72 | BBOX1 (0.38) | L3MBTL1LMNATSHRALDH1A1SMN1; SMN2 | |
| Sulfuric Acid SCHEMBL6912106 | 0.72 | NAAA (0.41) | LMNATSHRALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL9082257 | 0.72 | BBOX1 (0.38) | L3MBTL1LMNATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL12829898 | 0.72 | CASP2 (0.46) | L3MBTL1LMNATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL7204674 | 0.72 | CASP2 (0.52) | L3MBTL1LMNATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL688115 | 0.72 | FAAH (0.57) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762174-B1 | BETA-ALETHINE WITH MELPHALAN OR CYCLOPHOSPHAMIDE; PREVENTS CLINICAL APPEARANCE OF A NEOPLASTIC OR PRE-NEOPLASTIC CONDITION; IMMUNOMODULATION; ENHANCING CELL GROWTH, VITALITY, DIFFERENTIATION; ANTISENESCENCE | DOVETAIL TECHNOLOGIES, INC. | 2004-07-13 | — | — | US | disclosed |
| US-6498150-B2 | USEFUL IN ENHANCING VACCINATION, INCREASING SYNTHESIS AND FUNCTION OF BLOOD CELL COMPONENTS, AND ENHANCING ANTITUMOR EFFECTS | DOVETAIL TECHNOLOGIES, INC. | 2002-12-24 | — | — | US | disclosed |
| US-6451853-B1 | Small molecules that elicit a polarized Th1 response and for modulation of cellular immunity | DOVETAIL TECHNOLOGIES, INC | 2002-09-17 | — | — | US | disclosed |
| US-20020035118-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | DOVETAIL TECHNOLOGIES INC. | 2002-03-21 | — | — | US | disclosed |
| US-6007819-A | Methods of inducing immunity using low molecular weight immune stimulants | DOVETAIL TECHNOLOGIES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1999042099-A1 | LOW MOLECULAR WEIGHT COMPOUNDS ADMINISTERED TOGETHER WITH ANTI-CANCER AGENTS TO TREAT CANCER AND PHARMACEUTICAL COMPOSITIONS THEREOF | DOVETAIL TECHNOLOGIES INC. (US) | 1999-08-26 | — | — | WO | disclosed |
| WO-1999042097-A1 | SMALL MOLECULES THAT ELICIT A POLARIZED TH1 RESPONSE AND FOR MODULATION OF CELLULAR IMMUNITY | DOVETAIL TECHNOLOGIES INC. (US) | 1999-08-26 | — | — | WO | disclosed |
| WO-1997014306-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | DOVETAIL TECHNOLOGIES, INC. (US) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035118-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | ACP1, CD14, HPGDS | L3MBTL1 4021/4885LMNA 3542/4885TSHR 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.